Claude Wischik
Amministratore Delegato presso TauRx Pharmaceuticals Ltd.
Posizioni attive di Claude Wischik
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
TauRx Pharmaceuticals Ltd.
 TauRx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore. | Amministratore Delegato | 01/01/2002 | - |
| Presidente | 01/01/2002 | - | |
| Fondatore | 01/01/2002 | - | |
TauRx Therapeutics Ltd.
 TauRx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology TauRx Therapeutics Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases. It offers tau aggregation inhibitor, LMTX, a global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTXT. The company was founded by Claude Wischik and K M Seng in 2002 and is headquartered in Singapore. | Presidente | 01/01/2002 | - |
| Fondatore | 01/01/2002 | - |
Storia della carriera di Claude Wischik
Statistiche
Distribuzione geografica
| Singapore | 3 |
Posizioni
| Founder | 2 |
| Chairman | 2 |
| Chief Executive Officer | 1 |
Settori
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
TauRx Pharmaceuticals Ltd.
TauRx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore. | Health Technology |
TauRx Therapeutics Ltd.
TauRx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology TauRx Therapeutics Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases. It offers tau aggregation inhibitor, LMTX, a global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTXT. The company was founded by Claude Wischik and K M Seng in 2002 and is headquartered in Singapore. | Health Technology |
- Borsa valori
- Insiders
- Claude Wischik
- Esperienza